In Myriad’s $270M deal for Crescendo Bioscience, biotech and digital health converge
Myriad Genetics (Nasdaq: MYGN) has acquired Crescendo Bioscience in a $270 million deal. The move helps Myriad move into the autoimmune market. It also adds a mobile and web-based molecular diagnostic platform for rheumatoid arthritis to help patients manage their condition and improve engagement with physicians. It also gives Safeguard (NYSE: SFE) a big exit […]